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ischemia, arrhythmia, and heart failure. Signal transduction pathways important in the pathogenesis of hypertrophy have been the target of many recent investigations, with angiotensin II (ANG II) emerging as a key molecule both in compensatory cardiac hypertrophy and in the pathogenesis of progressive myocardial dysfunction leading to heart failure (48, 54) . Despite the importance of ANG II in cardiac hypertrophy, the signaling cascades downstream of ANG II receptor activation remain to be fully elucidated.
The small GTP-binding protein Rac1, a member of the Rho family of GTPases (51) , has emerged as an important proximal molecule in the hypertrophic response induced by a variety of extracellular signals in cardiovascular cells (17) . Hypertrophic agonists such as endothelin-1 and phenylephrine stimulate Rac1 activation in cultured cardiac myocytes (7) , and adenovirus (Ad)-mediated expression of a dominant-negative (AdN17Rac1) or a constitutively active mutant of Rac1 (AdV12Rac1) has been shown to abolish or exacerbate, respectively, phenylephrine-induced hypertrophic responses (36) . Transgenic mice expressing V12Rac1 specifically in myocardium develop dilated cardiac hypertrophy (50) , and increased activation of Rac1 has been observed in left ventricles from patients with ischemic cardiomyopathy as well as dilated cardiomyopathy (29) . In vascular smooth muscle cells (VSMC), ANG II has been shown to cause a rapid activation of Rac1 (39, 40) , and AdN17Rac1 inhibits ANG II-induced hypertrophic signaling (40) in this cell type. There is some evidence that Rac1 plays a role in the ANG II-mediated hypertrophic response in cardiomyocytes (53) , although the precise mechanisms are not fully understood.
The signaling pathways linking activated Rac1 and cellular hypertrophy may involve multiple molecules, although recent studies have focused on the participation of NADPH oxidase (6, 17, 29, 40) . This oxidase is a multi-subunit enzyme composed of a membrane-bound heterodimeric subunit (p22 phox and gp91 phox ) and several cytoplasmic regulatory subunits including Rac1, p47 phox , and p67 phox (4) . Recently, several homologs of gp91 phox , termed the NADPH oxidase or Nox family of enzymes (gp91 phox has been renamed Nox2), have been identified in several cardiovascular cell types including endothelial cells (26) and VSMC (24) . These different homologs have been shown to play an agonist-specific role in regulation of reactive oxygen species (ROS) generation and cellular hypertrophy in these various cells (6) . In VSMC, ANG II increases expression of Nox1, and a Nox1-containing NADPH oxidase is required for ANG II-induced ROS generation and hypertrophy (24, 49) . Much less is known about the Nox enzymes in cardiomyocytes, although one recent study (5) implicates Nox2 in ANG II-induced cardiac hypertrophy. However, because these in vivo studies utilized global knockout of Nox2, the role of this homolog in cardiomyocytes and the potential effect of compensatory increases in the expression of other Nox homologs in the heart and in other tissues are not known. Moreover, relative expression of the different Nox homologs in cardiomyocytes has not been established.
Activation of numerous growth-promoting signaling cascades in cardiomyocytes has been shown to require ROS (52) . In particular, the serine-threonine kinase Akt (Akt) has been identified recently as a target of ROS and is a key downstream mediator of various agonists that cause cellular hypertrophy (55) . Overexpression of a constitutively active mutant of Akt has been shown to increase cell surface area and expression of the cardiac hypertrophy marker atrial natriuretic peptide (ANP) (33, 37) . In vivo, pressure overload leads to rapid activation of Akt in the myocardium, and these changes are correlated with increased cardiac hypertrophy (32) . Furthermore, transgenic mice overexpressing Akt from a cardiomyocyte-specific promoter exhibit cardiac hypertrophy and enhanced myocardial contractility (22) . However, a direct role of Akt signaling in ANG II/ROS-mediated cardiomyocyte hypertrophy has not been demonstrated.
Here we tested the hypothesis that Nox2-mediated superoxide (O 2 Ϫ ⅐) production and activation of Akt play a critical signaling role in ANG II-stimulated cardiomyocyte hypertrophy. We took advantage of the specificity of genetic approaches to inhibit cytoplasmic O 2 Ϫ ⅐ generation and Akt activation in primary rat neonatal cardiomyocytes. Our results show that 1) blockade of Rac1 activation or inhibition of Nox2 expression by small interference RNA (si-Nox2) abolished both ANG II-stimulated ROS generation and cellular hypertrophy in primary neonatal rat cardiomyocytes, 2) ANG II activates Akt through an O 2 Ϫ ⅐-dependent mechanism in cardiomyocytes, and 3) Akt is a key regulator of ANG II-induced cardiomyocyte hypertrophy.
MATERIALS AND METHODS

Animals and Cardiomyocyte Cell Culture
Female Sprague-Dawley rats with pups (Harlan, Indianapolis, IN) were used. All protocols were approved by the University of Iowa Animal Care and Use Committee. The H9C2 cardiac myoblast cell line was purchased from the American Type Culture Collection (Manassas, VA) and cultured as described (20) . Primary neonatal cardiomyocytes were dissociated from the hearts of 2-day-old rat pups (12-14 pups/culture) and cultured using the Neonatal Cardiomyocyte Isolation System (Worthington, Lakewood, NJ) as described (42) . After two 30-min preplatings to reduce contamination with other cell types, myocytes were cultured in DMEM supplemented with 100 mol/l bromodeoxyuridine (BrdU). Addition of BrdU has been shown to retard growth of cardiac fibroblasts (37) . All experiments were performed after 24 h of incubation under serum-free conditions.
Recombinant Adenoviral Vectors
Construction and characterization of E1-deleted adenoviral vectors encoding human Cu/ZnSOD (AdCu/ZnSOD), HA-tagged dominantnegative Rac1 (AdN17Rac1), dominant-negative Akt in which alanine has been substituted for threonine 308 and serine 473 (AdDNAkt, HAtagged), or the control vector (AdBgL II) have been described previously (2, 60, 62). Concentrations of virus that induce efficient gene transfer without cell death have been optimized previously (2, 15, 57, 60, 62) . Appropriate subcellular compartment targeting of AdCu/ ZnSOD also has been established (57) . N17Rac, human Cu/ZnSOD, and DNAkt levels were determined by Western blot analysis as described (15, 57) . Appropriate cytoplasmic targeting of AdCu/ ZnSOD was verified by double immunostaining as described (57, 60) . All gene transfer occurred 24 h before experimentation.
Measurement of Rac1 Activation
ANG II-stimulated activation of Rac1 was analyzed using the Rac Activation Assay Kit (Upstate, Charlottesville, VA) as described (60) . Briefly, noninfected or AdN17Rac1-or AdBgL II-infected H9C2 cells were stimulated with vehicle, ANG II alone (5 or 30 min, 100 nmol/l), or ANG II subsequent to a 30-min pretreatment with the AT 1 receptor blocker losartan (100 mol/l). GTP-bound Rac1 was separated using agarose beads conjugated to the p21 (Rac1)-binding domain, resolved by SDS-PAGE, and Western blot analysis was performed using an anti-Rac1 antibody. Relative band intensity was quantified using Quant Pro1 software (Bio-Rad).
Two-Dimensional Cell Surface Area Analysis
Two-dimensional (2-D) measurements of cardiomyocyte surface area were performed essentially by the method of Simpson (42) . Briefly, primary cardiomyocytes were left untreated or were infected with AdBgL II, AdCu/ZnSOD, AdN17Rac1, or AdDNAkt for 24 h before treatment with vehicle, ANG II alone (100 nmol/l, 48 h), or ANG II subsequent to pretreatment with losartan (100 mol/l, 30 min) for 48 h. After stimulation, cells were incubated with CellTracker Green (10 mol/l, Molecular Probes) for 30 min, and fluorescent images were captured using a Zeiss LSM 510 laser confocal microscope. 2-D cell surface area was calculated for individual cells in each group using Image J analysis software (National Institutes of Health; NIH), and values are expressed as fold change relative to vehicletreated cells.
3-D Cell Volume Analysis
Cardiomyocytes grown on chamber slides were treated as described above for 2-D analysis. After loading with CellTracker Green, cells were fixed in 3.7% paraformaldehyde for 30 min, coverslipped, and imaged using the Zeiss confocal microscope. A z-series of 2-D images for each cardiomyocyte was generated with a 1-m interslice spacing as previously described (38) . All images were loaded into Voxblast 3-D analysis software (Vaytek, Fairfield, IA) and reconstructed into 3-D images. 3-D volume for each cell was calculated as the sum of 2-D surface area measurements from all slices multiplied by the interslice distance. This sequence was repeated for all cells in each sample group. 3-D volume measurements are expressed as fold change relative to vehicle-treated cells.
Measurement of ROS Generation in Cardiomyocytes
Electron spin resonance spectroscopy. Electron spin resonance (ESR) studies were performed according to published methods (46) with minor modifications. Briefly, noninfected or AdN17Rac1-, AdCu/ZnSOD-, or AdBgL II-infected cardiomyocytes were collected by trypsin digestion and resuspended in HBSS containing 50 mmol/l spin trap 5,5-dimethyl-L-pyrroline-N-oxide (DMPO; Sigma). Cells were then stimulated with vehicle, ANG II (100 nmol/l), or ANG II after losartan pretreatment (100 mol/l, 30 min), and ESR measurements were performed for 30 min using an X-band Bruker EMX spectrometer (Karlsruhe, Germany) at room temperature. Instrument settings were as follows: 1G modulation amplitude, 9.79-GHz microwave frequency, 100-kHz modulation frequency, 40- (60, 61) . Briefly, subconfluent cardiomyocytes were loaded with DHE (1 mol/l, Molecular Probes) for 30 min before treatment with vehicle or ANG II (100 nmol/l). Fluorescent images were captured before and after 30 min of ANG II stimulation, using confocal microscopy. Fluorescence intensity was quantified in individual cells using Image J analysis software (NIH), as described (60) , and expressed relative to pre-ANG II (0 min) values.
Quantitative Real-Time PCR Detection of Nox Homologs
Total RNA was isolated and reverse transcribed from rat primary cardiomyocytes and cardiac left ventricles. Quantitation of Nox1, Nox2, and Nox4 transcript levels was performed by amplification of cDNA prepared from total RNA with an ABI 7000 or 7700, using SYBR Green and primers specific for Nox1, Nox4, Nox2, and 18S mRNA. Primers were designed using Primer Express software (version 1.5, PE Biosystems, Foster City, CA), and were targeted to nonhomologous regions of the mRNA sequences of rat. All primers were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). The primers used were as follows: Nox1 sense, 5Ј-CTACAG-TAGAAGCCAACAGGCCAT-3Ј; Nox 1 anti-sense, 5Ј-ACTGT-CACGTTTGGAGACTGGATG-3Ј; Nox2 sense, 5Ј-CCCTTTGGTA-CAGCCAGTGAAGAT-3Ј; Nox2 anti-sense, 5Ј-CAATCCCAGCTC-CCACTAACATCA-3Ј; Nox4 sense, 5Ј-GGATCACAGAAGGTCC-CTAGCAG-3Ј; and Nox4 anti-sense, 5Ј-GCAGCTACATGCACAC-CTGAGAA-3Ј.
Standard amplification conditions were utilized according to the manufacturer's specification (PE Biosystems). Quantification of Nox1, Nox4, and Nox2 mRNA levels in the samples was performed by calculating copy number from standard curves generated from pure templates as described previously (24) . Data are expressed as transcript copy number relative to 18S copy number in a 100-ng total RNA sample.
Small Interference RNA Expression Plasmids
To accomplish intracellular expression of small interference RNA (siRNA), we designed short hairpin RNA (shRNA) constructs encoding inverted sequences of 21 base pairs with 3Ј-overhangs and separated by a six-nucleotide loop (5Ј-TATCGC). The shRNA cassette is designed such that, after annealing of two complementary oligos, the cassette has a 5Ј-blunt end and 3Ј-EcoRI cutting site for cloning into an expression plasmid (pacAd5CMV K-N pA, University of Iowa Vector Core). In this plasmid, the cytomegalovirus (CMV) promoter is used to drive expression of GFP as a reporter for siRNA expression. Downstream of this reporter, the shRNA constructs were cloned along with the U6 promoter to drive expression of shRNA in transfected cells. Each candidate shRNA clone was sequenced to verify that it retained 100% homology to Nox2. Initially, we tested three different shRNA sequences spaced throughout the mRNA of Nox2 (GenBank NM-023965) designed using general rules for siRNA selection described previously (13) . In the initial screening, the most effective siRNA directed against Nox2 (5Ј-GAGTGGTGTGTGAAT-GCCAGA-3Ј) was located 370 -390 bases (exon 5) from the start codon.
As a control, we have designed a random negative control siRNA (si-RNC) in collaboration with Integrated DNA Technologies (IDT, Coralville, Iowa). The DNA sequence for RNC, 5Ј-GGTTACCG-CAACGAGGTTTGC-3Ј, was generated from random sequence generator software designed by the bioinformatics group at IDT. A sequence analysis pipeline was designed to first screen candidate sequences for similarity against the mouse transcriptome and then subsequently remove candidate sequences that contained similarity to sequences within the human, mouse, and rat genomes. First, 21 nucleotide-length candidate sequences were generated with equal probabilities of the 4 nucleotides. Second, these sequence fragments were aligned by the Smith Waterman algorithm with the Mus musculus mRNA library, the rna.fa.gz file downloaded from ftp.ncbi. nlm.nih.gov/genomes/M_musculus/RNA/. In ranking the candidate sequences by their longest contiguous ungapped match, three sequence fragments containing 14 contiguous matches were selected. To verify the mismatch properties, these three candidates were searched against the entire genome sequences from Homo sapiens, M. musculus, and Rattus norvegicus with basic local alignment search tool (BLAST) (1) . The BLAST parameter of word size was set to 7 and the expectation value to 1,000.
siRNA Experiments
Primary cardiomyocytes were transfected with 6 g of the appropriate plasmid using FuGENE 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN) for 72 h under serum-free conditions. To examine the effect of si-Nox2 on cardiomyocyte hypertrophy, cells were then stimulated with vehicle or ANG II for 48 h and loaded with CellTracker Red, and 2-D cell surface was measured as described above. For determination of the effect of si-Nox2 on ROS production, green fluorescent protein (GFP)-positive cardiomyocytes were first sorted by fluorescence-activated cell sorting (FACS, FACSDiVa; Becton Dickinson, Franklin Lakes, NJ). ROS levels in GFP-positive si-Nox2 or si-RNC expressing cardiomyocytes and nontransfected (GFP-negative) cardiomyocytes were determined by ESR as described above. The efficiency and selectivity of si-Nox2 was confirmed using real-time PCR as described above. To confirm the findings at the protein level, Western blotting was performed using an anti-Nox2 antibody (BD Biosciences, San Jose, CA) as described (3).
Measurement of Akt Kinase Activity
ANG II-stimulated activation of Akt in cardiomyocytes was analyzed using the Akt Kinase Assay Kit (Cell Signaling Technology, Beverly, MA) as described (15) . Cardiomyocytes were stimulated with ANG II (100 nmol/l) for 0, 2, 5, and 10 min. In separate studies, Akt activation was determined in cardiomyocytes pretreated with the AT 1 receptor antagonist losartan (100 mol/l, 30 min) or infected with AdDNAkt, AdCu/ZnSOD, or AdBgL II before stimulation with ANG II (10 min). Immunoprecipitated Akt was incubated with ATP and glycogen synthase kinase (GSK)-3␣/␤ fusion protein, and Akt activity was determined by Western blot using an anti-phospho-GSK-3␣/␤ antibody.
Statistical Analysis
Data are expressed as means Ϯ SE and were analyzed by ANOVA (after Bartlett's test of homogeneity of variance), followed by the Newman-Keuls correction for multiple comparisons. Differences were considered significant at P Ͻ 0.05.
RESULTS
Ad-Mediated Expression of Dominant-Negative Rac1, Dominant-Negative Akt, and Human Cu/ZnSOD
To establish the optimal protocol for Ad-mediated expression of the Rac1 mutant (AdN17Rac1), dominant-negative Akt (AdDNAkt), and Cu/ZnSOD (AdCu/ZnSOD), the embryonic rat cardiac myoblast cell line H9C2 was used. As shown in the representative Western blot in Fig. 1A , infection of H9C2 cells with HA-tagged AdN17Rac1 (n ϭ 3) resulted in a concentration-dependent increase in expression of N17Rac1, with 100 pfu/cell causing robust N17Rac1 expression in healthy cells.
Representative Western blots shown in Fig. 1 , B and C, demonstrate that infection of cells with HA-tagged AdDNAkt (n ϭ 3) and AdCu/ZnSOD (n ϭ 3) resulted in concentrationdependent increases in expression of DNAkt and Cu/ZnSOD, respectively. It should be noted that 100 pfu/cell of AdDNAkt caused cell death in 10 -20% of cells as indicated by remodeling and detachment of cells from the culture dishes, and so in all subsequent experiments, 50 pfu/cell of AdDNAkt and 100 pfu/cell of AdCu/ZnSOD and AdN17Rac1 were used. None of these proteins was observed in noninfected (n ϭ 3) or AdBgL II-infected (n ϭ 3) cells.
To demonstrate proper subcellular targeting of Cu/ZnSOD, double immunohistochemistry was performed. Infection of H9C2 cells with 100 pfu/cell of AdCu/ZnSOD resulted in gene transfer in Ͼ90% of cells. Appropriate localization to the cytoplasm was demonstrated by the lack of double labeling of human Cu/ZnSOD (red) and mitochondria (green) (i.e., no yellow staining in merged image) (Fig. 1D) . This corroborates our earlier findings in other cell types (57) .
AdN17Rac1 Abolishes ANG II-Induced Rac1 Activation and Cardiomyocyte Hypertrophy
To confirm the efficacy of the N17Rac1 mutant to inhibit ANG II-induced activation of Rac1, we measured Rac1 activity in ANG II-stimulated H9C2 cells. ANG II caused an increase in Rac1 activity by 5 min, and this was sustained for 30 min (Fig. 2A, left) . AdN17Rac1 and losartan were equally effective at blocking the ANG II-induced increase in Rac1 activation at the 30-min time point, whereas infection of cells with AdBgL II had no effect on ANG II-stimulated Rac1 activation ( Fig. 2A, right) .
Having verified the effectiveness of AdN17Rac1 in blocking the ANG II-stimulated Rac1 activation, we next utilized this dominant-negative mutant to examine the role of Rac1 in ANG II-mediated hypertrophy in primary cardiomyocytes. In the first series of experiments, we determined the effect of AdN17Rac1 on 2-D cell surface area. Data from four separate experiments showed that 48-h stimulation with ANG II resulted in nearly a doubling of cardiomyocyte surface area compared with vehicle-treated cells (Fig. 2B) . Expression of N17Rac1 virtually abolished the ANG II-induced increase in 2-D cell surface area, and the extent of inhibition was comparable with that produced by losartan pretreatment (Fig. 2B) . Importantly, the hypertrophic response remained intact in AdBgL II-treated cells, confirming the specificity of AdN17Rac1. In addition, AdN17Rac1 alone did not have an effect on the surface area of unstimulated cardiomyocytes.
To confirm that increases in cell surface area reflect an increase in cell volume, we also performed a second series of experiments using 3-D analysis. As shown in the summary data in Fig. 2C , ANG II stimulation caused a threefold increase in cardiomyocyte volume relative to vehicle treatment. Similar to the 2-D studies, both AdN17Rac1 and losartan abolished this increase in 3-D cell volume, whereas AdBgL II-infected cells exhibited the same hypertrophic response to ANG II as noninfected cells (Fig. 2C ).
AdN17Rac1 and AdCu/ZnSOD Attenuate ANG II-Stimulated ROS Generation in Cardiomyocytes
To determine whether ANG II-induced Rac1 activation is coupled to cardiomyocyte hypertrophy via activation of a ROS-generating NADPH oxidase, we next examined the effect of N17Rac1 on ANG II-stimulated increases in intracellular ROS generation in cardiomyocytes by ESR and DHE staining. As seen in the representative ESR tracings and summary data in Fig. 3A , treatment of cardiomyocytes with ANG II caused a threefold increase in ROS production compared with vehicletreated cells. This response was significantly attenuated by pretreatment of cells with AdN17Rac1 or the AT 1 receptor antagonist losartan, but not by the control vector AdBgL II. Our findings that AdCu/ZnSOD also inhibited the ANG IIinduced ESR signal (Fig. 3A) provide corroborative evidence that the free radical species involved is O 2 Ϫ ⅐. As further confirmation of this, the representative DHE fluorescence images and summary data presented in Fig. 3B demonstrate that AdN17Rac1 significantly attenuated ANG II-induced increases in O 2 Ϫ ⅐, whereas the response was unaffected by AdBgL II. Importantly, vehicle treatment had no effect on basal ROS generation over the 30-min time course of the study. As further verification of the specificity of the assay, pretreatment of cardiomyocytes with AdCu/ZnSOD virtually abolished the ANG II-induced increases in DHE staining (Fig. 3B) . Taken together, these results suggest that a Rac1-regulated NADPH oxidase plays a central role in ANG II-stimulated O 2 Ϫ ⅐ generation in cardiomyocytes.
Abundance of Nox1, Nox2, and Nox4 Transcripts in Cardiomyocytes
Having established that a Rac1-regulated NADPH oxidase plays a critical role in ANG II-induced cardiomyocyte hypertrophy, we next sought to identify the predominant Nox homolog(s) comprising the oxidase in cardiomyocytes. Using quantitative real-time PCR, we compared the expression of Nox1, Nox2, and Nox4 in primary rat neonatal cardiomyocytes. Under basal conditions, Nox2 is most abundantly expressed, with Nox 4 at intermediate levels and Nox1 at very low but detectable levels in isolated cardiomyocytes (Fig. 4A) . To compare this profile with the in vivo situation, real-time PCR experiments were also carried out in adult rat left ventricle (LV). Similar to isolated cardiomyocytes, Nox2 was expressed at significantly higher levels than Nox4 in these LV samples (133 Ϯ 23 vs. 67 Ϯ 12 copies/18S copies ϫ 10 6 ; n ϭ 3, P Ͻ 0.05), while Nox1 levels were barely detectable (0.2 Ϯ 0.03 copies/18S copies ϫ 10 6 ).
si-Nox2 Attenuates ANG II-Induced ROS Generation and Cardiomyocyte Hypertrophy
Because we found that Nox2 is the most abundant Nox homolog in cardiomyocytes, the next goal was to establish a functional role for this oxidase using siRNA to selectively inhibit Nox2 expression. First, to verify the specificity and effectiveness of si-Nox2, we performed quantitative real-time PCR on primary cardiomyocytes transfected with this reagent. Nox2 expression was decreased by Ͼ95% in cells treated with si-Nox2 compared with control si-RNC-treated cells (Fig. 4B) . Importantly, si-Nox2 did not significantly alter expression of either Nox1 or Nox4 (si-Nox2 vs. si-RNC; Fig. 4B ). In addition, Nox2 protein levels were nearly undetectable in si-Nox2-treated cultures compared with si-RNC (Fig. 4C) , confirming the effectiveness of this siRNA in silencing Nox2 expression in cardiomyocytes.
To determine whether Nox2 is an important source of the ROS generated by ANG II in these cells, we compared ESR spectra in si-Nox2-transduced cells (GFP positive) with nontransduced (GFP-negative) cells from the same culture sample (after FACS). ANG II treatment caused a significant increase in ROS generation in si-Nox2-negative cardiomyocytes, whereas the si-Nox2-positive cardiomyocytes showed markedly attenuated ANG II-induced ROS generation (Fig. 5A) . Further confirming specificity of si-Nox2-mediated inhibition, transfection of cardiomyocytes with the control si-RNC had no effect on the ANG II-stimulated increase in ROS production (Fig. 5A) . These results confirm that a Nox2-containing NADPH oxidase is a key source of ANG II-induced ROS generation in cardiomyocytes.
Next, to establish a functional role for Nox2 in ANG II-induced cardiomyocyte hypertrophy, nontransfected cardiomyocytes (GFP negative) and cardiomyocytes transfected with si-Nox2 or si-RNC (GFP positive) were stimulated with ANG II for 48 h, and 2-D cell surface analyses were performed. As shown in the summary data in Fig. 5B , ANG II-induced increases in cardiomyocyte surface area were virtually abolished in cells treated with si-Nox2. In contrast, the ANG II-stimulated cardiomyocyte hypertrophy remained intact in cells transfected with the control plasmid si-RNC.
AdDNAkt and AdCu/ZnSOD Abolish ANG II-Induced Akt Activation and Cardiomyocyte Hypertrophy
To investigate the redox-sensitive pathways downstream of ANG II-induced Nox activation and ROS generation, we examined the role of Akt. This is an important signaling molecule in ANG II/ROS cascades involved in hypertrophy in other cell types (55) . First, to determine the time course of Akt activation by ANG II and confirm the feasibility of using AdDNAkt to inhibit this pathway, we measured Akt activation by ANG II in primary cardiomyocytes. ANG II caused a rapid, time-dependent increase in Akt activity that was detectable after 2 min of stimulation, was significantly elevated by 5 min, and remained elevated through 10 min (Fig. 6A ). AdDNAkt and losartan were equally effective at blocking the ANG II-stimulated increase in Akt activation (10 min), whereas infection of cells with the control virus AdBgL II had no effect on the Akt activation profile. These results show that ANG II stimulates Akt activation via AT 1 receptors and validate the use of AdDNAkt to investigate the role of Akt in ANG II signaling in cardiomyocytes.
Next, to determine the role of O 2 Ϫ ⅐ in ANG II-induced activation of Akt, we measured Akt kinase activity in cardiomyocytes pretreated with AdCu/ZnSOD. The representative Western blot and summary data shown in Fig. 6B demonstrate that ANG II-induced increases in Akt activity were significantly inhibited by AdCu/ZnSOD, whereas infection with AdBgL II had no effect. These results suggest that O 2 Ϫ ⅐ is a key upstream signaling molecule in the activation of Akt in cardiomyocytes.
Finally, to establish whether there are links between O 2 Ϫ ⅐ and Akt in ANG II-induced cardiomyocyte hypertrophy, we measured 2-D cell surface area in primary cardiomyocytes infected with either AdDNAkt or AdCu/ZnSOD. As shown in the summary data from three separate experiments in Fig. 7 , both AdDNAkt and AdCu/ZnSOD significantly reduced the ANG II-stimulated increases in hypertrophy, whereas AdBgL II did not have any effect (Fig. 7) . Importantly, neither AdDNAkt nor AdCuZnSOD alone significantly altered basal cardiomyocyte surface area (Fig. 7) . Taken together, these results suggest that O 2 Ϫ ⅐-mediated activation of the Akt signaling cascade is required for ANG II-stimulated cardiomyocyte hypertrophy.
DISCUSSION
ANG II is a potent hypertrophic agent that regulates cardiomyocyte size and activates numerous growth-related signal transduction pathways (11, 48, 54) . Here, using a variety of selective genetic reagents, we present evidence that O 2 Ϫ ⅐ radicals derived from a Rac1-activated, Nox2-containing NADPH oxidase play a key role in the proximal signaling cascade involved in ANG II-induced cardiomyocyte hypertrophy. Furthermore, Akt activation is downstream of O 2 Ϫ ⅐ generation in this pathway. The following evidence supports this conclusion: 1) ANG II induced a rapid and robust activation of Rac1, an essential cofactor for agonist-stimulated assembly and activation of NADPH oxidase; this occurred in a time course that paralleled ROS production; 2) pretreatment of cardiomyocytes with a dominant-negative isoform of Rac1 inhibited ANG II-dependent Rac1 activation, intracellular ROS production, and cardiomyocyte hypertrophy; 3) targeted scavenging of cytoplasmic O 2 Ϫ ⅐ by Ad-mediated expression of cytosolic human Cu/ZnSOD markedly inhibited ANG II-induced increases in ROS production and cardiomyocyte hypertrophy; 4) Nox2 homolog expression was greater than that of Nox4 in isolated cardiomyocytes and in adult LV tissue, while Nox1 expression was barely above the detection limit; 5) siRNA-mediated inhibition of Nox2 expression in cardiomyocytes attenuated both ANG II-induced O 2 Ϫ ⅐ generation and cardiomyocyte hypertrophy; and 6) ANG II induced O 2 Ϫ ⅐-dependent activation of Akt, and Ad-mediated expression of dominant-negative Akt abolished ANG II-induced cardiomyocyte hypertrophy.
Since the first report by Nakamura et al. (35) that nonspecific antioxidants inhibit ANG II-stimulated cardiomyocyte hypertrophy, a search has been underway to identify the cellular source(s) of ROS production involved in pathological hypertrophic signaling in the heart. Although early studies implicated both mitochondria (21) and xanthine oxidase (12) as sources of increased ROS, more recent studies suggest that NADPH oxidase may be the predominant source of ROS generation in the myocardium. Shah and colleagues (Li et al., Ref. 25) have shown increased expression of p22 phox , Nox2, p67 phox , and p47 phox in the LV of aortic-banded guinea pigs. In the failing myocardium from patients with ischemic or dilated cardiomyopathy, an increase in Rac1 GTPase activity is associated with increased ROS production compared with healthy Fig. 4 . Expression of different Nox homologs in rat primary cardiomyocytes and efficiency and selectivity of si-Nox2. A: summary real-time PCR data showing levels of Nox1, Nox2, and Nox4 mRNA in rat primary cardiomyocytes. B: real-time PCR data showing the effects of si-Nox2 and control si-RNC on Nox homolog expression. For both, copy nos. of Nox homologs were calculated from standard curves generated using purified Nox1, Nox2, and Nox4 cDNA and expressed relative to 18S mRNA. cDNA template equivalent to 100 ng of total RNA was used. Data are means Ϯ SE (n in bars shows no. of independent cultures). *P Ͻ 0.05 vs. Nox1 and Nox4; †P Ͻ 0.05 vs. si-RNC. C: representative Western blots showing Nox2 protein levels in cardiomyocytes treated with si-Nox2 (right) compared with controls (left). Blots were stripped and reprobed for ␤-actin to control for equal sample loading. Data are representative of 2 separate cardiomyocyte cultures. hearts (29) . Moreover, in animal models of hypertrophy-induced heart failure, as well as in ischemic and dilated cardiomyopathy, ROS levels are increased in cardiac tissue (10, 21, 45) , and treatment with nonselective antioxidants has been shown to retard progression of LV hypertrophy and dysfunction (23, 30, 34) . However, the full cascade linking ANG II, Rac1-regulated NADPH oxidase, ROS generation, and ultimately cardiomyocyte hypertrophy has not been definitively established. Using a cardiomyocyte cell culture model system and gene manipulation approaches, our results show that blockade of NADPH oxidase assembly and activity via dominant-negative Rac1 abolished both ANG II-induced O 2 Ϫ ⅐ generation and cardiomyocyte hypertrophy. Moreover, in complementary experiments where cytoplasm-targeted superoxide dismutase (SOD) was used to scavenge intracellular ROS, ANG II-induced cardiomyocyte hypertrophy was markedly attenuated. These results demonstrate that NADPH oxidasemediated intracellular O 2 Ϫ ⅐ generation is a key regulator of ANG II-induced hypertrophy.
Extensive evidence from vascular studies suggests that endothelial cells, fibroblasts, and VSMC express the Nox homologs Nox1, Nox2, and Nox4 (47) , but the levels of the different homologs and the regulation of their expression are cell type specific (24, 27) . To identify the Nox homolog(s) comprising NADPH oxidase and mediating ANG II hypertrophic signaling in cardiomyocytes, we coupled quantitative PCR with an siRNA approach. We observed that Nox2 expression was greater than that of Nox4 in cultured cardiomyocytes, while Nox1 expression was barely detectable. Recently, two studies (5, 31) have shown that ROS generation and cardiac hypertrophy induced by systemic infusion of ANG II were attenuated in mice with gene-targeted deletion of Nox2. However, because of global gene deletion in these knockout mice and infiltration of NADPH oxidase-positive macrophages in the diseased myocardium, the precise identity of the Nox enzyme(s) mediating ANG II signaling in cardiac tissue remained unclear. Thus, to extend these studies, we used siRNA to selectively attenuate Nox2 expression in a cardiomyocyte culture system in vitro. Our results show that selective inhibition of Nox2 expression attenuated ANG II-induced ROS generation and cardiomyocyte hypertrophy. Together, these in vitro and in vivo studies demonstrate that Nox2 is required for ANG II-dependent cardiac hypertrophy.
Although we have taken precautions during cardiomyocyte isolation and culture to minimize contamination from cardiac nonmyocyte cells (see MATERIALS AND METHODS), it is possible that our myocyte cultures may contain some nonmyocytes. Indeed, previous studies (9, 43) using almost identical protocols for isolation and culture of neonatal rat cardiomyocytes report up to 10 -15% nonmyocyte cells in myocyte cultures. Given the evidence that growth factors produced by nonmyocytes can lead to cardiomyocyte growth (28) , and that nonmyocytes may express different complements of Nox homologs (18) , further studies using pure cultures of cardiomyocytes by Percoll gradient centrifugation (19) will be needed to confirm the expression and function of different Nox homologs in ANG II-dependent cardiomyocyte hypertrophy.
Intensive investigation is currently focused on determining the identities of ROS mediating agonist-induced cellular hypertrophy. For example, in VSMC, Griendling (34) demonstrated that polyethylene-glycol (PEG)-encapsulated SOD markedly inhibited ANG II-induced increases in cardiomyocyte protein synthesis and ANF secretion, whereas the H 2 O 2 scavenger, a PEG-encapsulated catalase, had virtually no effect. However, because the subcellular localization of ROS scavenging by PEG-encapsulated SOD is unclear, and there was no evidence that PEG-encapsulated SOD inhibited cytoplasmic O 2 Ϫ ⅐ levels in this study, it was difficult to derive definitive conclusions. Therefore, to confirm that O 2 Ϫ ⅐ radicals are key signaling intermediates in ANG II-induced hypertrophic signaling, we utilized a genetic approach to manipulate intracellular O 2 Ϫ ⅐ levels. Our results show that selective scavenging of cytoplasmic O 2 Ϫ ⅐ with Ad-delivered Cu/ZnSOD markedly attenuated both ANG II-stimulated increases in cardiomyocyte size and intracellular O 2 Ϫ ⅐ levels. These results, combined with the previous studies discussed above, support the hypothesis that O 2 Ϫ ⅐ radicals mediate ANG II-stimulated hypertrophic signaling in cardiomyocytes. Further studies utilizing similar genetic approaches, but with Ad-GPx1 and Ad-catalase alone and in conjunction with Cu/ ZnSOD, will be required to confirm this hypothesis.
One of the primary mechanisms by which ROS influence cellular function is through activation of redox-sensitive kinases and their downstream targets. In particular, phosphatidylinositide 3-kinase (PI3K)-Akt, p38MAPK, ERKs, and JNK are activated by both oxidative stress and pressure overload in the myocardium (32, 56) , and Akt has emerged as a key signaling molecule regulating cardiomyocyte survival and hypertrophy (56) . Mice with cardiac-specific expression of constitutively active Akt spontaneously develop cardiac hypertrophy (22, 41) . On the other hand, inactivation of Akt by dominant-negative Akt inhibits cardiomyocyte hypertrophy in vitro, induced by growth-promoting cytokines including tumor necrosis factor-␣ (TNF-␣) (8) , and constitutively active PI3K-induced cardiac hypertrophy in vivo (41) . Griendling and colleagues (Ushio-Fukai et al., Ref. 55) provided the first evidence that ANG II activates Akt via ROS-mediated activation of PI3K, and that activated Akt is required for ANG II-induced hypertrophy in VSMC. In noncardiovascular cell types, ANG II activation of Akt was shown to be dependent on NADPH oxidase activation, as inhibition of this oxidase by expression of N17Rac1 or siRNA against Nox4 has been shown to markedly decrease Akt activity and cellular hypertrophy (16, 59) . Our results support and extend these studies to cardiomyocytes by demonstrating that scavenging of O 2 Ϫ ⅐ with AdCu/ZnSOD significantly inhibited ANG II-stimulated increases in Akt activation. Interestingly, the extent of inhibition was similar to that observed with the AT 1 receptor antagonist losartan, suggesting a prominent role for ROS in Akt signaling in cardiomyocytes. Furthermore, our data show that pretreatment of cardiomyocytes with AdDNAkt abolished the ANG II-induced increase in cell surface area. Taken together, these data suggest that ANG II-stimulated increases in Nox2-mediated O 2 Ϫ ⅐ radical formation activate the Akt signaling pathway, and that this pathway plays a central role in cardiomyocyte hypertrophy.
It should be noted that cell surface area and volume measurements alone may not be sufficient as indexes of cardiomyocyte hypertrophy. Further studies using other indexes of cardiomyocyte hypertrophy, i.e., increases in protein synthesis and induction of fetal genes like ANF and ␤-myosin heavy chain (44), will be required to confirm the role of NADPH oxidase-derived ROS and Akt activation in ANG II-dependent cardiomyocyte hypertrophy. Future studies could be aimed at extending these studies using additional indexes of hypertrophy as well as identifying the targets of activated Akt in this hypertrophic response.
In summary, we have demonstrated that an increase in cytoplasmic O 2 Ϫ ⅐ generation by a Rac1-regulated Nox2 enzyme, with subsequent activation of Akt, plays a key role in ANG II-induced cardiomyocyte hypertrophy. We propose that low levels of O 2 Ϫ ⅐ might play an important role in regulating myocardial function under normal physiological conditions, but dysregulation of the cardiomyocyte redox state through an increase in Nox activity due to overactivation of the reninangiotensin system is involved in the development of pathological cardiac hypertrophy by an Akt-dependent signaling cascade. As such, we speculate that therapeutic strategies targeting Nox2 in the heart may prove beneficial for the prevention of cardiac hypertrophic disease.
